# FDA 483 - Long Island Jewish Medical Center - May 01, 2026

Source: https://www.keypedia.com/records/483/long-island-jewish-medical-center/50ea6735-ecbe-4e24-8d38-b514148afbe6

> FDA 483 for Long Island Jewish Medical Center on May 01, 2026. Product: biologics. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Long Island Jewish Medical Center
- Inspection Date: 2026-05-01
- Product Type: biologics
- Office Name: New York District Office
- Summary: An FDA inspection of Long Island Jewish Medical Center's Blood Bank revealed significant deficiencies in its operations. The facility failed to consistently establish, maintain, and follow standard operating procedures for the storage, distribution, and visual inspection of blood products, as well as for handling mislabeled specimens. Additionally, the inspection found a failure to maintain adequate processing, quality control, and general records, including those related to investigations, blood reconstitution, and specific processing cycles.

## Related Documents

- [483 - 2022-03-10](https://www.keypedia.com/records/483/long-island-jewish-medical-center/4a0127ce-16fb-44a6-93fb-b6520ce5e471)
- [483 - 2024-03-15](https://www.keypedia.com/records/483/long-island-jewish-medical-center/164661e2-970e-49d5-a92b-ee8838e5ad86)

## Related Officers

- [Investigator](https://www.keypedia.com/people/irina-gaberman/c863b2de-4c64-40d2-a390-289d293e5a8f)

Company: https://www.keypedia.com/companies/long-island-jewish-medical-center/5a96c7ae-ca09-44a4-9c04-c05f5312d771

Office: https://www.keypedia.com/offices/new-york-district-office/9fa3d265-16ca-438d-8a6e-b47f60dc260d